SCHEMBL19780142

SCHEMBL19780142

CCCC(C)c1cccc(Cl)c1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.41
TSHR P16473 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
LMNA P02545 2/20 0.41
GABRG2 P18507 2/20 0.41
GABRB3 P28472 2/20 0.41
GABRB2 P47870 2/20 0.41
FAAH O00519 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
HPGD P15428 1/20 0.41
GABRB1 P18505 1/20 0.41
PTGS1 P23219 1/20 0.41
SLC6A2 P23975 1/20 0.41
HTR2C P28335 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
HTR2B P41595 1/20 0.41
GABRA2 P47869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23491328 0.87 SOAT1 (0.38) GABRA1TSHRCYP1A2CYP3A4LMNA
SCHEMBL1834375 0.87 GABRA1 (0.54) GABRA1TSHRCYP1A2CYP3A4LMNA
SCHEMBL19779505 0.85 TSHR (0.57) GABRA1TSHRCYP1A2CYP3A4LMNA
SCHEMBL4955633 0.81 TSHR (0.52) GABRA1TSHRCYP1A2CYP3A4LMNA
SCHEMBL21776127 0.81 PNMT (0.55) TSHRCYP1A2CYP3A4LMNASLC6A2
SCHEMBL4314320 0.81 GABRA1 (0.65) GABRA1TSHRCYP1A2CYP3A4LMNA
SCHEMBL9284882 0.81 ADRB2 (0.44) TSHRCYP1A2CYP3A4LMNASLC6A2
SCHEMBL9232403 0.81 ADRB2 (0.44) TSHRCYP1A2CYP3A4LMNASLC6A2
SCHEMBL4443322 0.80 ALDH1A1 (0.46) GABRA1TSHRCYP1A2CYP3A4LMNA
SCHEMBL8821811 0.79 CYSLTR2 (0.41) TSHRCYP1A2CYP3A4CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2018-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016252-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 GABRA1 322/4885TSHR 70/4885CYP1A2 4769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.